Biocon Ltd. NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

349.00 1.20 (0.35%)

3.6M

NSE+BSE Volume

NSE 08 Oct, 2025 3:31 PM (IST)

US FDA Approval

Biocon's arm gets US FDA nod for its ANDA for Rifaximin tablets, with a $1.8 billion market size See details

Biocon Ltd. quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents